6-145635468-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_005670.4(EPM2A):c.495G>A(p.Trp165*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000254 in 1,613,866 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_005670.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152186Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251428Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135890
GnomAD4 exome AF: 0.0000260 AC: 38AN: 1461680Hom.: 0 Cov.: 30 AF XY: 0.0000275 AC XY: 20AN XY: 727156
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152186Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74360
ClinVar
Submissions by phenotype
Lafora disease Pathogenic:1
The p.Trp165Ter variant in EPM2A has been reported in 4 individuals with Lafora disease (PMID: 14722920, 17389303, 34755096), and has been identified in 0.003% (40/1179864) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs781291421). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID: 381553) and has been interpreted as likely pathogenic by GeneDx and as pathogenic by Invitae. This nonsense variant leads to a premature termination codon at position 165, which is predicted to lead to a truncated or absent protein. Loss of function of the EPM2A gene is an established disease mechanism in autosomal recessive Lafora disease. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive Lafora disease. ACMG/AMP Criteria applied: PVS1, PM2_supporting (Richards 2015). -
not provided Pathogenic:1
Reported previously in an individual with Lafora disease, however no additional information was provided for this individual (PMID: 14722920); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, Brewer2021[Case Report], 20738377, 31589614, 14722920, 31440721, 34755096) -
Progressive myoclonic epilepsy Pathogenic:1
This sequence change creates a premature translational stop signal (p.Trp165*) in the EPM2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EPM2A are known to be pathogenic (PMID: 20738377). This variant is present in population databases (rs781291421, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Lafora disease (PMID: 14722920). ClinVar contains an entry for this variant (Variation ID: 381553). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at